Q3 2025 · 13F-HR
5AM Venture Management, LLCholdings as filed
Filed 2025-11-14 · accession 0001799883-25-000002
$273.0M
Reported value
25
Positions
2025-09-30
Period end
The Brief · 5AM Venture Management, LLC · Q3 2025
AI · grounded in 13F
5AM Venture Management, LLC established a new position in SKYE valued at $38.0M. The fund also initiated new stakes in TRDA for $24.7M and PHVS for $19.9M. Other new additions include CAMP at $17.6M and CNTA at $16.5M. Total assets under management stand at $273.0M across 25 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 83086J200 | SKYE | SKYE BIOSCIENCE INC | $38.0M | 13.9% | 9,681,763 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $24.7M | 9.04% | 4,256,379 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $19.9M | 7.29% | 797,600 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $17.6M | 6.45% | 5,869,091 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $16.5M | 6.05% | 680,945 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $15.9M | 5.82% | 736,595 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $15.8M | 5.79% | 772,477 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $15.0M | 5.48% | 1,050,000 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $14.4M | 5.26% | 365,053 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $13.1M | 4.81% | 939,298 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $12.9M | 4.71% | 497,270 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $11.8M | 4.32% | 5,405,404 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $9.0M | 3.30% | 170,000 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $8.2M | 3.00% | 572,665 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $8.0M | 2.94% | 511,660 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $7.2M | 2.63% | 478,972 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $6.8M | 2.47% | 2,353,304 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $4.0M | 1.46% | 310,000 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $3.5M | 1.27% | 800,000 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $2.9M | 1.08% | 995,841 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $2.5M | 0.91% | 476,200 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $2.5M | 0.90% | 541,666 | Common | SOLE |
| 75120L100 | RLYB | RALLYBIO CORP | $1.8M | 0.66% | 3,630,724 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $739,900 | 0.27% | 490,000 | Common | SOLE |
| 59045L205 | MRSN | MERSANA THERAPEUTICS INC | $405,072 | 0.15% | 52,200 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.